Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3715 - Pooled data analysis of the safety and tolerability of intravenous Pelareorep in combination with chemotherapy in 500 + cancer patients

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Immunotherapy

Presenters

ANDRES GUTIERREZ

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

A.A. GUTIERREZ, C. Reid, M. Crawford, K. Cheetham, A. Dzugalo, M. Parsi, A. Penman, N. Noronha, D. Galindez, R. O'Flynn, M. Coffey

Author affiliations

  • Clinical Development, Oncolytics Biotech Inc, T2N 1X7 - Calgary,/CA
More

Resources

Abstract 3715

Background

Oncolytic viruses are promising cancer immunotherapies but questions have been raised regarding their safety. Pelareorep (REOLYSIN, R), an unmodified Reovirus Dearing strain, selectively replicates and lyses cancer cells and induces anti-tumor immunity. To date, 900+ patients (pts) have been treated with intravenous (IV) pelareorep. In a phase 2 trial, its combination with paclitaxel improved overall survival (17.4m) vs paclitaxel (10.4m) in metastatic breast cancer (MBC) pts (HR 0.65, 80% CI 0.46-0.91, p = 0.1; Berstein et.al. AACR2017). A pooled analysis was thus conducted to better characterize pelareorep’s safety profile in combinations with paclitaxel.

Methods

1417 pts have been enrolled in 36 trials: 934 pts received IV pelareorep and 359 were in control arms. Data from 8 trials with paclitaxel (P), paclitaxel + pelareorep (PR), carboplatin + paclitaxel (CP) or carboplatin + paclitaxel + pelareorep (CPR) were pooled. Standard doses of P (weekly) and CP were administered. Pelareorep IV dose was 3x1010 TCID50 (5-6 doses q21-28 d). Various advanced solid tumors were evaluated, including the 81 pts with MBC.

Results

A total of 563 pts were included in P (86), PR (95), CP (118) or CPR (264) groups. Median age (59-62 y) and ECOG 0-1 status (90-96%) were similar across the groups. All pts in P or PR had received prior chemo but only 26% in CP and 38% in CPR. Fatigue was the most common grade ≥3 treatment related adverse event (TRAE) in PR (9.5%) and CPR (8.3%) vs P (8.1%) and CP (2.5%). Grade ≥3 neutrophil count decreased and/or WBC decreased were more frequent in PR (15.8%/17.9%) than in P (5.8%/3.5%), but addition of pelareorep did not increase the frequency or severity of other grade ≥3 TRAEs with P or CP. Serious TRAEs (%) of interest in P vs PR and CP vs. CPR, included: fever (0 vs 3.2 & 0 vs 3.8), febrile neutropenia (0 vs 1.1 & 3.4 vs 3.4), sepsis (1.2 vs 0 & 0 vs 1.5) and flu-like syndrome (0 vs 1.1 & 0 vs 0.8).

Conclusions

This is the largest database reported to date examining the safety of an IV viral agent. Pelareorep’s administration, in combination with paclitaxel or carboplatin-paclitaxel, is safe and well tolerated. Continued evaluation in a registration trial is planned.

Clinical trial identification

NCI-US

NCI-GOG 0186H (NCT01199263). Ongoing, but not recruiting

NCI-8601 (NCT01280058). Ongoing, but not recruiting NCI- Canada (CCTG)

NCIC-CTG IND.213 (NCT01656538). Ongoing, but not recruiting Oncolytics Biotech Inc:

REO011 – UK (Karapanagiotou et al. CCR 2012) Completed

REO015 (NCT00753038) Completed

REO016 (NCT00861627) Completed

REO018 (NCT01166542). Completed

REO021 (NCT00998192) Completed

Legal entity responsible for the study

Studies were sponsored/conducted by NCI-US, NCI-Canada (CCTG) or Oncolytics Biotech Inc. See section of Clinical Trial Identification

Funding

NCI-US and NCI- Canada conducted their own studies and Oncolytics Biotech only provided the drug. Some studies were fully supported and conducted by Oncolytics. Details can be found in the Clinical Trial Identification section

Disclosure

A.A. Gutierrez: Chief Medical Officer and an employee of Oncolytics Biotech Inc. (or one of its affiliated corporations). Own shares in or have options to purchase shares in Oncolytics Biotech Inc. C. Reid: Paid consultant of Oncolytics Biotech. M. Crawford: Employee of Oncolytics Biotech Inc. (or one of its affiliated corporations) and own shares in or have options to purchase shares in Oncolytics Biotech Inc. K. Cheetham, A. Penman, N. Noronha: Employee of Oncolytics Biotech Inc. (or one of its affiliated corporations) and own shares in or have options to purchase shares in Oncolytics Biotech Inc. A. Dzugalo: Employee of Oncolytics Biotech Inc. (or one of its affiliated corporations) and own shares in or have options to purchase shares in Oncolytics Biotech Inc. M. Parsi, D. Galindez, R. O\'Flynn: Paid consultant of Oncolytics Biotech. M. Coffey: President and CEO of Oncolytics Biotech Inc. As an employee of Oncolytics Biotech Inc. (or one of its affiliated corporations) he owns shares in or have options to purchase shares in Oncolytics Biotech Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.